Bicnu
Bicnu Brand names, Bicnu Analogs
Bicnu Brand Names Mixture
- No information avaliable
Bicnu Chemical_Formula
C5H9Cl2N3O2
Bicnu RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Bicnu fda sheet
Bicnu msds (material safety sheet)
Bicnu Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Bicnu Molecular Weight
214.049 g/mol
Bicnu Melting Point
31 oC
Bicnu H2O Solubility
< 0.1 g/100 mL at 18 °C
Bicnu State
Solid
Bicnu LogP
1.256
Bicnu Dosage Forms
Powder for solution; Wafer
Bicnu Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Bicnu Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Bicnu Absorption
5 to 28% bioavailability
Bicnu side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Bicnu Patient Information
No information avaliable
Bicnu Organisms Affected
Humans and other mammals
